Docetaxel prolongs life in men with hormone refractory prostate cancer
AUTOR(ES)
Gottlieb, Scott
FONTE
BMJ Publishing Group Ltd.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=523104Documentos Relacionados
- Clodronate for treatment of bone metastases in hormone refractory prostate cancer
- Quality of life of men treated with brachytherapies for prostate cancer
- Recovery of hormone sensitivity after salvage brachytherapy for hormone refractory localized prostate cancer
- Brief assessment of priority symptoms in hormone refractory prostate cancer: The FACT Advanced Prostate Symptom Index (FAPSI)
- Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy